SAGE BIONETWORKS: Form 990, tax year 2018

View the entire original 990 at ProPublica ↗

Organization
SAGE BIONETWORKS (EIN 26-4489946)
Tax period
2018-01-01 to 2018-12-31
Filed
2019-10-15
IRS object ID
201922899349300212
Schema version
2018v3.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2019-10-15T09:45:17-07:00ReturnTs
Tax Period End2018-12-31TaxPeriodEndDt
Return Type990ReturnTypeCd
Tax Period Begin2018-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN264489946EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1SAGE BIONETWORKSBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlSAGEBusinessNameControlTxt
Phone2069288250PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line12901 Third Ave Ste 330AddressLine1Txt
CitySeattleCityNm
State AbbreviationWAStateAbbreviationCd
ZIP98121ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonLara MangravitePersonNm
Person TitlePresidentPersonTitleTxt
Phone2069288250PhoneNum
Signature2019-10-15SignatureDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address207.109.76.122IPv4AddressTxt
FieldValueIRS element (for citing)
Tax2018TaxYr
Build TS2019-02-21 02:37:17ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLara MangravitePrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line12901 Third AveAddressLine1Txt
Address Line2Ste 330AddressLine2Txt
CitySeattleCityNm
State AbbreviationWAStateAbbreviationCd
ZIP98121ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$17,958,815GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website Addresswww.sagebionetworks.orgWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2009FormationYr
Legal Domicile StateWALegalDomicileStateCd
Activity Or MissionSage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement.ActivityOrMissionDesc
Voting Members Governing Body6VotingMembersGoverningBodyCnt
Voting Members Independent5VotingMembersIndependentCnt
Total Employee71TotalEmployeeCnt
Total Volunteers5TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$7,337,401PYContributionsGrantsAmt
CY Contributions Grants$15,555,426CYContributionsGrantsAmt
PY Program Service Revenue$3,001,123PYProgramServiceRevenueAmt
CY Program Service Revenue$2,402,775CYProgramServiceRevenueAmt
PY Investment Income$258PYInvestmentIncomeAmt
CY Investment Income$614CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$10,338,782PYTotalRevenueAmt
CY Total Revenue$17,958,815CYTotalRevenueAmt
PY Grants And Similar Paid$786,047PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$1,886,803CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$6,762,079PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$8,601,831CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$40,673CYTotalFundraisingExpenseAmt
PY Other Expenses$3,456,621PYOtherExpensesAmt
CY Other Expenses$4,233,682CYOtherExpensesAmt
PY Total Expenses$11,004,747PYTotalExpensesAmt
CY Total Expenses$14,722,316CYTotalExpensesAmt
PY Revenues Less Expenses-$665,965PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$3,236,499CYRevenuesLessExpensesAmt
Total Assets BOY$3,193,164TotalAssetsBOYAmt
Total Assets EOY$5,921,898TotalAssetsEOYAmt
Total Liabilities BOY$1,753,320TotalLiabilitiesBOYAmt
Total Liabilities EOY$1,245,555TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$1,439,844NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$4,676,343NetAssetsOrFundBalancesEOYAmt
MissionSage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. Sage Bionetworks is a non-profit research organization that seeks to develop predictors of disease and accelerate health research through the creation of open systems, incentives, and standards. We create strategies and platforms that empower researchers to share and interpret data on a colossal scale, crowdsource tests for new hypotheses, and contribute to knowledge through community challenges.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$9,647,005ExpenseAmt
Grant$7,068,028GrantAmt
Revenue$10,893,528RevenueAmt
DescResearch Communities and Challenges: Sage Bionetworks conducts research independently as well as with collaborators worldwide across a variety of disease areas. We work to redefine how complex biological data is gathered, shared and used through open systems, incentives, and norms. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. Research: As biological research has become more data intensive, the breadth of data and expertise required to address research problems has expanded. It requires the integrated efforts of a distributed set of researchers (such as bench/data scientists, data engineers, project managers, administrators, governance experts, and clinical researchers) with shared interests and complementary resources. Effective collaboration depends on a collective ability to work together in trusted ways that lead to translatable biomedical insights. We call this scientific coordination. Sage's scientific coordination stack includes: 1) hypothesis and data generation, 2) data curation, 3) analysis, 4) interpretation, and 5) dissemination. We focus on building a federated network of individuals who bring diverse expertise and approaches to develop robust solutions. New research projects initiated in 2018 included: * Human Tumor Atlas Network (HTAN) - Funded by NCI, Sage is the data coordinating center for HTAN which aims to leverage the power of human genome sequencing and other state-of-the-art profiling technologies, to analyze changes in individual tumors. * VEOIBD Portal - Funded by the Helmsley Charitable Trust, the VEOIBD Portal aggregates Consortium-identified genotypic data with data from other data sources to find causes and treatments for Inflammatory Bowel Disease (IBD). Ongoing research communities included: * Agora - funded by the NIA, Agora is a platform that enables researchers to access information about how genes are associated with Alzheimer's disease. It aggregates lines of biological evidence from multiple sources, so researchers can better prioritize which genes they want to follow up on for development of new therapies. * All of Us - a program to engage over one million participants in a study to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. * CD2H (National Center for Data to Health) - with aims to foster collaboration across more than 50 premier medical research institutions within the prestigious Clinical and Translational Science Awards, or CTSA, network. * Cancer Systems Biology Consortium (CSBC) - Sage serves as the Coordinating Center for the CSBC and Physical Sciences in Oncology Network (PS-ON) program. This five-year award builds on the work of the NCI funded Sage Bionetworks' Center for Cancer Systems Biology from 2010 through 2015. * iAtlas -together with the Institute for Systems Biology, Sage was funded by the Cancer Research Institute to build iAtlas, an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types. * KiAAP - funded by Bill and Melinda Gates Foundation, Sage was engaged to support the distributed efforts of BMGF funded data scientists across a number of ongoing research projects in neurocognitive development. * MODEL-AD Consortium - Sage runs the Knowledge Portal, the distribution site for data, analysis results, analytical methodology and research tools generated by the AMP-AD and M2OVE-AD Consortia. * Synodos Consortium - a first-of-its-kind Neurofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis type 2. * The Cancer Genome Atlas (TCGA) - with data from 12 cancers, TCGA is an ongoing effort to simultaneously analyze molecular platforms for patterns across cancer types. * Tumor Neoantigen Selection Alliance (TESLA) - a global research alliance with 30 public and private groups to advance the development of more effective personalized cancer treatments. Funded by the Parker Institute for Cancer. Challenges: With algorithms playing an increasing role in biomedical analysis and patient care, there's a need for a more rigorous framework for evaluating and improving the capabilities of these algorithms. Sage Bionetworks has pioneered the development of concepts and infrastructure to objectively evaluate algorithms across a broad spectrum of biomedical domains, including bioinformatics, biomedical informatics, and clinical trials. As a trusted partner in hosting challenges and benchmarking initiatives, Sage serves as a broker between data generators and data modelers. We combine technology with biomedical and data science expertise to facilitate the objective assessment of algorithms on critical data sets, including proprietary data and algorithms that cannot be broadly shared. Sage works with the DREAM community to host open challenges. With 13 years of successful Challenges, DREAM is recognized as a leader in biomedical competitions, successfully motivating research teams to address fundamental questions about systems biology and translational medicine and to advance computational methods. DREAM challenges invite participants to propose solutions - fostering collaboration and building communities in the process. Over 20,000 people from around the world and across disciplines have contributed their expertise to Challenges. Sage Bionetworks provides institutional support, along with the infrastructure to host challenges via our Synapse platform Active Challenges hosted on the Synapse platform in 2018 included: * ACIC 2018 Causal Inference Challenge -held at the annual Atlantic Causal Inference Conference (ACIC), participants of this challenge focused on computational methods of inferring causal effects from real-world healthcare-related data. * DREAM Single Cell Transcriptomics Challenge - participants were asked to reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. * IDG Drug-Kinase Binding Challenge - seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts. * Multi-targeting Drug DREAM Challenge - seeks to diversify the methods used for rational design of drugs with multiple target proteins.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$4,414,233ExpenseAmt
Grant$3,554,233GrantAmt
Revenue$4,984,896RevenueAmt
DescDigital Health Smartphones and other wearable sensors have put touchscreens and high-fidelity sensors into the pockets of billions of people. These technologies provide an opportunity to paint a rich understanding of health and disease in the everyday world outside of the clinic. They also provide communication tools that allow participants a more active voice in research programs. With our Digital Health program, we work to advance health research through practices that support the design, development and implementation of studies that use technology to monitor health outside of the clinical setting, and the analysis and sharing of the resulting study data. We help to derive and test digital biomarkers. We evaluate analytical methodologies to benchmark best practices in study design and data analysis. Sage's Digital Health program is built around Bridge, a technology platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. Bridge is composed of HIPAA-compliant web services and multi-language SDKs that facilitate: registration and informed consent to participate in research; web-based tools to design and schedule study surveys and sensor-based tasks; acquisition and secure transfer of multiple data types (surveys, sensors, audio, video, or custom data types); a study management portal with daily dashboard updates; and de-identification and storage of study data in our collaborative data science environment, Synapse. Digital Health studies active in 2018 included: * Cardiovascular Fitness Module - As part of the PMI All of Us study, Sage is developing methods to use the sensors built into smartphones to assess Cardiorespiratory fitness in a way that can scale to potentially one million participants and become a generally useful tool for clinical research. * Chronic Anemia - conducted in partnership with Celgene, Journey PRO incorporates wearable and mobile technologies to assess mobility, cardiovascular health, cognitive performance, and quality of life assessments. * Multiple Sclerosis - with pharmaceutical partner Novartis, Sage launched elevateMS, a mobile app to monitor the severity of MS symptoms and to track relapse * Sage, together with study partners at OHSU, publicly released the first data set from the Mole Mapper melanoma mobile health study. * mPower Public Researcher Portal - an updated version of the mPower iPhone study piloting new approaches to monitoring key indicators of Parkinson Disease was active in 2018. A subset of data from this portal along with data contributed by MJFF was included in the PD Digital Biomarker DREAM Challenge launched in 2017.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$0TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant$0TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue$0TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses$14,061,238TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Temp Or Permanent Endowments0TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other AssetsYes (1)ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 Footnote0IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (1)IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With Officer Ent0BusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (1)DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document19IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Employee71EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members6GoverningBodyVotingMembersCnt
Independent Voting Member5IndependentVotingMemberCnt
Family Or Business Rln0FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention Policy0DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process Other0CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonDiane GaryPersonNm
Phone2069288243PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line12901 Third Ave Ste 330AddressLine1Txt
CitySeattleCityNm
State AbbreviationWAStateAbbreviationCd
ZIP98121ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (16 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
Stephen Friend
Chairman of the Board1Yes (X)$0$0$0
Eric Schadt
Director/Chair of Scientific Advisory Board1Yes (X)$0$0$00
Tony Ford-Hutchinson
Director1Yes (X)$0$0$00
Gustavo Stolovitsky
Director1Yes (X)$0$0$00
Tetsu Maruyama
Director1Yes (X)$0$0$00
Lara Mangravite
President50$245,496$0$36,6440Yes (X)
Diane Gary
Secretary50$166,446$0$30,8370Yes (X)
John Wilbanks
Chief Commons Officer50$231,848$0$21,9810Yes (X)
Mike Kellen
Chief Technology Officer50$210,759$0$23,9470Yes (X)
Justin Guinney
Vice President, Computational Oncology50$195,821$0$36,0570Yes (X)
Larsson Omberg
Vice President, Systems Biology50$166,446$0$30,8320Yes (X)
Bruce Hoff
Director, Synapse Team50$166,334$0$39,6140Yes (X)
Erin Mounts
Principle SW Engineer50$161,735$0$30,5040Yes (X)
Dwayne Jeng
Principal SW Engineer50$156,897$0$19,9870Yes (X)
Alx Dark
Principle Software Engineer50$156,811$0$11,5290Yes (X)
John Woodburn
Director, Design50$154,831$0$19,8350Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$2,013,424TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$301,767TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K39IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (2 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
Stockard Simon
44564 SE 144th StNorth BendWA98045IT Design$152,386
Yuangang Guan
744 Eagle AveAnn ArborMI48103Scientific challenges$113,917
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K2CntrctRcvdGreaterThan100KCnt
Federated Campaigns$0FederatedCampaignsAmt
Membership Dues$0MembershipDuesAmt
Fundraising$0FundraisingAmt
Related Organizations$0RelatedOrganizationsAmt
Government Grants$10,622,261GovernmentGrantsAmt
All Other Contributions$4,933,165AllOtherContributionsAmt
Noncash Contributions$101,355NoncashContributionsAmt
Total Contributions$15,555,426TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescScientific CollaborationsDesc
Business541711BusinessCd
Total Revenue Column$2,402,775TotalRevenueColumnAmt
Related Or Exempt Func Income$2,402,775RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$2,402,775TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$614TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$614ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Real$0RealAmt
Personal$0PersonalAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$0SecuritiesAmt
Other$0OtherAmt
FieldValueIRS element (for citing)
Contri Rpt Fundraising Event$0ContriRptFundraisingEventAmt
Other Revenue Total$0OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$17,958,815TotalRevenueColumnAmt
Related Or Exempt Func Income$2,402,775RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$614ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$1,660,903TotalAmt
Program Services$1,660,903ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$225,900TotalAmt
Program Services$225,900ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$1,465,680TotalAmt
Program Services$1,218,969ProgramServicesAmt
Management And General$235,992ManagementAndGeneralAmt
Fundraising$10,719FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$5,733,150TotalAmt
Program Services$5,505,292ProgramServicesAmt
Management And General$209,658ManagementAndGeneralAmt
Fundraising$18,200FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$232,559TotalAmt
Program Services$217,633ProgramServicesAmt
Management And General$14,278ManagementAndGeneralAmt
Fundraising$648FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$919,508TotalAmt
Program Services$893,899ProgramServicesAmt
Management And General$23,077ManagementAndGeneralAmt
Fundraising$2,532FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$250,934TotalAmt
Program Services$232,870ProgramServicesAmt
Management And General$17,341ManagementAndGeneralAmt
Fundraising$723FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$62,696TotalAmt
Program Services$58,815ProgramServicesAmt
Management And General$3,643ManagementAndGeneralAmt
Fundraising$238FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$138,472TotalAmt
Program Services$129,901ProgramServicesAmt
Management And General$8,045ManagementAndGeneralAmt
Fundraising$526FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$38,737TotalAmt
Program Services$36,339ProgramServicesAmt
Management And General$2,251ManagementAndGeneralAmt
Fundraising$147FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$0TotalAmt
Fundraising$0FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$2,372,299TotalAmt
Program Services$2,355,780ProgramServicesAmt
Management And General$15,505ManagementAndGeneralAmt
Fundraising$1,014FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$49,173TotalAmt
Program Services$46,129ProgramServicesAmt
Management And General$2,857ManagementAndGeneralAmt
Fundraising$187FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$160,055TotalAmt
Program Services$150,148ProgramServicesAmt
Management And General$9,299ManagementAndGeneralAmt
Fundraising$608FundraisingAmt

Royalties RoyaltiesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$605,854TotalAmt
Program Services$568,352ProgramServicesAmt
Management And General$35,200ManagementAndGeneralAmt
Fundraising$2,302FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$364,570TotalAmt
Program Services$341,123ProgramServicesAmt
Management And General$22,008ManagementAndGeneralAmt
Fundraising$1,439FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$38,378TotalAmt
Program Services$37,287ProgramServicesAmt
Management And General$1,024ManagementAndGeneralAmt
Fundraising$67FundraisingAmt

Interest InterestGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$16,806TotalAmt
Program Services$15,766ProgramServicesAmt
Management And General$976ManagementAndGeneralAmt
Fundraising$64FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$29,139TotalAmt
Program Services$27,335ProgramServicesAmt
Management And General$1,693ManagementAndGeneralAmt
Fundraising$111FundraisingAmt

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$357,503TotalAmt
Program Services$338,797ProgramServicesAmt
Management And General$17,558ManagementAndGeneralAmt
Fundraising$1,148FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$14,722,316TotalAmt
Program Services$14,061,238ProgramServicesAmt
Management And General$620,405ManagementAndGeneralAmt
Fundraising$40,673FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$488,278BOYAmt
EOY$564,479EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$2,570,019BOYAmt
EOY$3,134,674EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$46,969BOYAmt
EOY$1,021,718EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$84,143BOYAmt
EOY$88,014EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$104,503LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$13,208LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$3,755BOYAmt
EOY$91,295EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt

Intangible Assets IntangibleAssetsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$1,021,718EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$3,193,164BOYAmt
EOY$5,921,898EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$759,381BOYAmt
EOY$750,306EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$993,939BOYAmt
EOY$457,667EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$37,582EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$1,753,320BOYAmt
EOY$1,245,555EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$1,280,854BOYAmt
EOY$2,352,896EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$158,990BOYAmt
EOY$2,323,447EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$1,439,844BOYAmt
EOY$4,676,343EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$3,193,164BOYAmt
EOY$5,921,898EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss$3,236,499ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$0NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts$0DonatedServicesAndUseFcltsAmt
Investment Expense$0InvestmentExpenseAmt
Prior Period Adjustments$0PriorPeriodAdjustmentsAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewYes (1)AccountantCompileOrReviewInd

Acct Compile Or Review Basis AcctCompileOrReviewBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit RequiredYes (1)FederalGrantAuditRequiredInd
Federal Grant Audit PerformedYes (1)FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$7,808,314CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$6,230,203CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$5,050,380CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$7,337,399CurrentTaxYearMinus1YearAmt
Current Tax Year$12,490,269CurrentTaxYearAmt
Total$38,916,565TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$0CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$0CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$0CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$0CurrentTaxYearMinus1YearAmt
Total$0TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$0CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$0CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$0CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$0CurrentTaxYearMinus1YearAmt
Total$0TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$7,808,314CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$6,230,203CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$5,050,380CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$7,337,399CurrentTaxYearMinus1YearAmt
Current Tax Year$12,490,269CurrentTaxYearAmt
Total$38,916,565TotalAmt
FieldValueIRS element (for citing)
Public Support Total170$38,916,565PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,802CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,056CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$380CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$258CurrentTaxYearMinus1YearAmt
Current Tax Year$614CurrentTaxYearAmt
Total$4,110TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$0CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$0CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$0CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$0CurrentTaxYearMinus1YearAmt
Total$0TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,552,869CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,464,542CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,230,377CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$3,001,123CurrentTaxYearMinus1YearAmt
Current Tax Year$2,402,778CurrentTaxYearAmt
Total$10,651,689TotalAmt
FieldValueIRS element (for citing)
Total Support$49,572,364TotalSupportAmt
Gross Receipts Rltd Activities$0GrossReceiptsRltdActivitiesAmt
Public Support CY1700.78505PublicSupportCY170Pct
Public Support PY1700.76345PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferenceSchedule A, Part II, Line 10FormAndLineReferenceDesc
ExplanationFee for service revenue from research collaborations.ExplanationTxt

Schedule B IRS990ScheduleB

Schedule D IRS990ScheduleD

Land LandGrp

FieldValueIRS element (for citing)
Investment Cost Or Other Basis$0InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis$0OtherCostOrOtherBasisAmt
Book Value$0BookValueAmt

Buildings BuildingsGrp

FieldValueIRS element (for citing)
Investment Cost Or Other Basis$0InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis$0OtherCostOrOtherBasisAmt
Depreciation$0DepreciationAmt
Book Value$0BookValueAmt

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Investment Cost Or Other Basis$0InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis$0OtherCostOrOtherBasisAmt
Depreciation$0DepreciationAmt
Book Value$0BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Investment Cost Or Other Basis$104,503InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis$0OtherCostOrOtherBasisAmt
Depreciation$13,208DepreciationAmt
Book Value$91,295BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Investment Cost Or Other Basis$0InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis$0OtherCostOrOtherBasisAmt
Depreciation$0DepreciationAmt
Book Value$0BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$91,295TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp

FieldValueIRS element (for citing)
DescPledges Receivable, net of current portionDesc
Book Value$1,021,718BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Other Assets$1,021,718TotalBookValueOtherAssetsAmt
Federal Income Tax Liability$0FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescDeferred building rentDesc
Amt$37,582Amt
FieldValueIRS element (for citing)
Total Liability$37,582TotalLiabilityAmt
Total Rev Etc Audited Fincl Stmt$17,958,815TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$0NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$0DonatedServicesAndUseFcltsAmt
Recoveries Prior Year Grants$0RecoveriesPriorYearGrantsAmt
Other Revenue$0OtherRevenueAmt
Revenue Not Reported$0RevenueNotReportedAmt
Revenue Subtotal$17,958,815RevenueSubtotalAmt
Investment Expenses Not Incld$0InvestmentExpensesNotIncldAmt
Other Revenues Not Included$0OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$0RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$17,958,815TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$14,722,316TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$0DonatedServicesUseFcltsAmt
Prior Year Adjustments$0PriorYearAdjustmentsAmt
Losses Reported$0LossesReportedAmt
Other Expenses Included$0OtherExpensesIncludedAmt
Expenses Not Reported$0ExpensesNotReportedAmt
Expenses Subtotal$14,722,316ExpensesSubtotalAmt
Investment Expenses Not Incld2$0InvestmentExpensesNotIncld2Amt
Other Expenses Not Included$0OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt$0ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$14,722,316TotalExpensesPerForm990Amt

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp

FieldValueIRS element (for citing)
RegionEurope (including Iceland and Greenland)RegionTxt
Offices0OfficesCnt
Employee0EmployeeCnt
Type Of Activities ConductedGrantmakingTypeOfActivitiesConductedTxt
Specific Services ProvidedData generation for our Coordinated biocomputational studies. To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. The TEP is meant to bridge the gap between identification of candidate targets, and the ability to launch a chemical biology or drug discovery program. A TEP will typically include purified protein, biochemical assays, crystal structures, and tool compounds. In some cases, the TEP will identify sequences for mutation in CRISPR/Cas9 loss-of function editing, but in most cases it will enable the initiation of a small molecule chemical probe or antibody discovery project by proving that the target is tractable and reducing the barrier to drug discovery.SpecificServicesProvidedTxt
Region Total Expenditures$225,900RegionTotalExpendituresAmt
FieldValueIRS element (for citing)
Total Office0TotalOfficeCnt
Total Employee0TotalEmployeeCnt
Total Spent$225,900TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtNon Cash AssistanceNonCashAssistanceAmt
Europe (including Iceland and Greenland)To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. All TEP components will be openly distributed as described in the resource sharing plan. Our previous experience of over a dozen TEP programs indicates that the availability of therapeutic hypothesis, evidence of druggability, and initial chemical hits for a new target will tempt a wide spectrum of medicinal chemists to launch more extensive chemical development programs.$162,928Wire Transfer$0
Europe (including Iceland and Greenland)Serve as experts in DREAM challenge organization, participate in designing the CTPAC-DREAM Proteogenomics Challenge, testing the challenge by doing the initial analysis (dry run), scoring participants submissions, and performing the sub-challenge metaanalysis of results.$39,220Wire Transfer$0
Europe (including Iceland and Greenland)Complete gene expression characterization of CRC cell lines and PDX models as well as in silico pharmacogenetic studies in cell lines. Complete xenotrials in molecularly stratified models and receive most of the clinical molecular data from collaborating pharma/academia clinical trials in order to perform correlative predictive and prognostic analyses. Complete data analysis from xenotrials, treatment biomarker interactions from clinical trials and summarize findings with the "investigator-driven' molecularly stratified clinical trial proposals to run in parallel of the MoTriColor study$23,752Wire Transfer$0
FieldValueIRS element (for citing)
Total501c3 Org0Total501c3OrgCnt
Total Other Org3TotalOtherOrgCnt
Transfer To Foreign Corp0TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp Ownership0ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSchedule F, Part I, Line 2FormAndLineReferenceDesc
ExplanationMonitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties.ExplanationTxt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (17 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINCash GrantCashGrantAmtNon Cash AssistanceNonCashAssistanceAmtPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
Institute for Systems Biology
401 Terry Ave NSeattleWA98109912003593$489,494$0Assist in the development of an integrative platform: the Pan-cancer Immune Atlas (iAtlas) to host the data and results derived from the PanCancerAtlas Immune Response Working Group and to provide external investigators witht the ability to reproduce results of the IRWG. Provide expertise related to the analyses of the metabolic and transcriptional regulatory networksand will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for Alzheimer's Disease. The Institute for Systems Biology will provide expertise related to the (dynamic) analyses of the metabolic and transcriptional regulatory networks and will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for the AMP-AD CC project.
Icahn School of Medicine at Mount Sinai
1 Gustave L Levy PlaceNew YorkNY11029136171197$325,616$0Perform computational and integrative analysis of the AMP/AD data sets to develop a set of high probability therapeutic targets necessary for their assessment and integration into drug discovery efforts for the Agora project. Image-guided studies to determine the contribution of breast cancer cells to metastatic outgrowth Leukemias for the CSBC project.
University of California San Diego
9500 Gilman DrLa JollaCA92093956006144$206,908$0To determine the test validity and test-retest reliability of smartphone-based measurement of CRF. To evaluate the feasibility and acceptability of using a smartphone application to measure CRF. This will be examined using a system usability scale and assessing compliance and overall satisfaction with the administered protocol. Provide expert consultation in the use of agile science methods for creating strategies for facilitating sustained engagement with the MPower 2.0 application. This includes providing expertise related to behavioral theory, human centered design, and measurement strategies. Develop an experimental design and broader strategy for gathering evidence to foster iterative improvement on mPower to foster improved sustained engagement with the tool.
Stanford University
450 Serra MallStanfordCA94305941156365$175,960$0Oversee the genomic profiling, analysis, and computational modeling of metastatic colorectal cancer patient data. Prioritize candidate metastasisassociated genes and provide for modeling in organoids. Contribute to the analysis of cell fitness and clone size distributions in the metastatic colon organoid models. Interpret the data from the microenvironmental arrays. Create a baseline model for future comparison using existing framework for Digital Mammography Challenge.
Fred Hutchinson Cancer Research Center
1100 Fairview Ave NSeattleWA98109237156071$56,144$0Study the mechanisms that underlie metastatic castrate resistant prostate cancer(CRPC). We will combine approaches from pharmacology, as well as cell and computational biology to identify kinases that are functionally important for driving cell growth and proliferation in CRPC. We will employ Kinome regression approach to: (1) identify kinases in CRPC cell lines and patient-derived organoid models and test in silico predicted candidate kinase inhibitors in 3D bone-mimetic cultures; and (2) validate the effect of candidate kinase inhibitors in in vivo CRPC bone metastasis models, followed by molecular characterization.
University of Pittsburgh
116 Atwood StPittsburghPA152133402250965591$56,016$0Combine approaches from pharmacology, as well as cell and computational biology to identify specific kinases that are functionally important for the growth of metastatic CRPC. We will also build a computational model to predict response to >300 naive kinase inhibitors in a physiological-relevant CRPC bone metastasis model. Further, we will probe the spatial nature of the kinase-driven signaling patterns in the tumors, which is critical to understanding the mechanisms of drug response. Overall, these studies have a strong potential to advance medical practices; a new therapeutic option for metastatic CRPC could give unprecedented hope to the providers and patients who currently face this disease with severely limited alternatives.Suite 201
The University of Texas MD Anderson Cancer Center
PO Box 4486HoustonTX77210746001118$55,976$0Validate in 3D the top kinase inhibitors selected in the 2D screening. These experiments will be performed on up to 3 prostate cancer cellular models, including cell lines and patient-derived xenografts, testing different concentration of the inhibitors.
Duke University
324 Blackwell StDurhamNC277013659560532129$52,160$0Metastasis is the primary cause of cancer patient mortality and is virtually uncurable. In colorectal cancer (CRC), which represents the third leading cause of cancer-related mortality in the United States, 10-20% of patients with Stage II disease and 50% with Stage III develop recurrence, while another 20% of patients present with metastases at diagnosis. Current targeted therapies for metastatic colorectal cancer (mCRC) prolong survival by mere months with little benefit in the adjuvant setting. Improved treatment strategies are thus urgently needed, but require characterization of the molecular drivers and microenvironmental determinants of the metastatic phenotype. Critically, the advent of advanced genome-engineering and lineage tracing technologies, 3-D organotypic culture systems and platforms to probe the tumor microenvironment provides an unprecedented opportunity for rapid, functional and phenotypic screens towards delineation of the genotype-phenotype map in cancer.Ste 850
Partners Healthcare System Inc
399 Revolution DrSomervilleMA021451465270273715$47,732$0Combine mouse mammary cancer models with high-resolution imaging to quantify early vs late disseminated cancer cells, outgrown metastases, and their colocalization and dynamics. To quantify behavior of disseminated cancer cells using laser scanning confocal microscopy and other techniques available at the MGH Center for Systems Biology.Ste 645
University of Massachusetts Worcester
55 Lake Ave NWorcesterMA016550002043167352$46,255$0There is an ongoing debate concerning whether early DCCs or late DCCs drive metastasis during the life of a patient when both population will likely co-exist. We hypothesize that in fact both early and late disseminated cancer cells (DCCs) cooperate to drive metastatic outgrowth. Here, we adopt an innovative interdisciplinary approach combining metastatic tumor modeling, tissue engineering, high-resolution in vivo microscopy, and integrative omics analysis to tackle the problem. We believe the success of this pilot proposal will provide novel strategies to combat the deadly metastatic diseases, as well as foster our future collaborations.
University of Arizona
220 W 6th StTucsonAZ85701742652689$38,685$0The goal of the project is to develop small molecules (from in silico docking on the CD44 binding pocket and peptidomimetics of CD44 peptide) and peptides (from the peptide array) to disrupt the interaction between CD44 and FERM domain-containing proteins. These tools will help to define if the proteins are druggable, and whether targeting protein-protein interactions can have a more specific effects than global inhibition of the ectodomain of CD44 using antibodies or small molecules. This will pave the way to testing therapeutic hypotheses for AMP-AD targets relating to protein-protein interactions.
Rutgers the State University of New Jersey
33 Knightsbridge RdPiscatawayNJ088543925226001086$36,570$0The research proposal outlines image-guided studies to determine the contribution of breast disseminated cancer cells to metastatic outgrowth.Room B112
Oregon Health & Science University
3181 SW Sam Jackson Park RdPortlandOR972393908931176109$21,269$0CSBC Pilot testing and optimization of MCAT/Her2 crainbow cells on MEMA platform and MEMA optimization and screening.L106OPAM
San Ysidro Health
1601 Precision Park LaneSan DiegoCA92173952801772$19,929$0San Ysidro Health (SYHealth) will participate in the "All of Us Research Program Sage Bionetworks - Federally Qualified Health Centers Consent Study" for participant recruitment and data collection. Findings from this study will be used immediately to improve, elaborate, and/or supplement AoURP informed consent materials for AoURP national launch. The project begins with formative work to determine study approach and contribute to study protocols and ends with data submission and analysis verification by the site PI.
Hudson River Healthcare Foundation
1037 Main StPeekskillNY105662913200151252$18,845$0Research Assistants (RAs) will recruit potential participants using a variety of techniques including engagement tabling in Barham House, a senior apartment building, at the Peekskill Kiley Center with the Community Action Program, and at local community venues like the Salvation Army, the Peekskill Library, and a local homeless shelter, in addition to health-center based recruitment. The RAs and Pilot Coordinator will liaise with community stakeholders to coordinate such recruitment efforts. Interested individuals are screened by RAs using the REALM-SF tool and, if eligible, invited to participate in a 1:1 interview or a focus group. Each session lasts approximately 1 hour and is facilitated and recorded by a Research Assistant. An additional RA participates for notetaking purposes as appropriate. In addition to these implementation activities, our PIs and Project Coordinators liaise with the other FQHCs involved, with Sage, and with MITRE to provide ongoing feedback on the REALM
University of Rochester
500 Joseph C Wilson BlvdRochesterNY14627160743209$7,667$0Provide consultation on interpretation and guidance on mPower 1.0 analysis and design and scientific strategy for mPower 2.0 data collection.
New York University
One Park AveNew YorkNY10016135562308$5,677$0Data generation and analysis for the Proteogenomics Computational Challenge6th Floor
FieldValueIRS element (for citing)
Total501c3 Org17Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSchedule I, Part I, Line 2FormAndLineReferenceDesc
ExplanationIn 2018, Sage Bionetworks issued grants, contributions, and prizes. Contributions were given in support of an awarded institution's project and prizes were awarded to research challenge winners. Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
First Class Or Charter TravelYes (X)FirstClassOrCharterTravelInd
Written Policy Ref T And E ExpnssYes (1)WrittenPolicyRefTAndEExpnssInd
Substantiation RequiredYes (1)SubstantiationRequiredInd
Compensation CommitteeYes (X)CompensationCommitteeInd
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments0AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Lara Mangravite
President$245,496$0$0$0$0$0$0$0$36,644$0$282,140$0$0$0
Diane Gary
Secretary$166,446$0$0$0$0$0$0$0$30,837$0$197,283$0$0$0
John Wilbanks
Chief Commons Officer$231,848$0$0$0$0$0$0$0$21,981$0$253,829$0$0$0
Mike Kellen
Chief Technology Officer$210,759$0$0$0$0$0$0$0$23,947$0$234,706$0$0$0
Justin Guinney
Vice President, Computational Oncology$195,821$0$0$0$0$0$0$0$36,057$0$231,878$0$0$0
Larsson Omberg
Vice President, Systems Biology$166,446$0$0$0$0$0$0$0$30,832$0$197,278$0$0$0
Bruce Hoff
Director, Synapse Team$166,334$0$0$0$0$0$0$0$39,614$0$205,948$0$0$0
Erin Mounts
Principle SW Engineer$161,735$0$0$0$0$0$0$0$30,504$0$192,239$0$0$0
Dwayne Jeng
Principal SW Engineer$156,897$0$0$0$0$0$0$0$19,987$0$176,884$0$0$0
Alx Dark
Principle Software Engineer$156,811$0$0$0$0$0$0$0$11,529$0$168,340$0$0$0
John Woodburn
Director, Design$154,830$0$0$0$0$0$0$0$19,835$0$174,665$0$0$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
Schedule J, Part I, Line 1aAll travel conducted per the company travel policy.
Schedule J, Part I, Line 3Setting executive compensation is the responsibility of the Board of Directors Compensation Committee.

Schedule M IRS990ScheduleM

FieldValueIRS element (for citing)
Form8283 Received0Form8283ReceivedCnt
Any Property That Must Be Held0AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts0ReviewProcessUnusualNCGiftsInd
Third Parties Used0ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSchedule M, Part I, Line 33FormAndLineReferenceDesc
ExplanationReceived In-Kind legal services.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
Form 990, Part VI, Section B, Line 11bThe 990 is reviewed by the company's Vice President of Operations and President prior to filing.
Form 990, Part VI, Section B, Line 12cSage Bionetworks has a Financial Conflict of Interest Policy (FCOI) that complies with the National Institutes of Health-specific requirements promoting objectivity in research, 42 CFR Part 50 subpart F. On an annual basis, Sage Bionetworks Officers, Directors, and members of committees of Board of Directors authorized to act on behalf of the board, and employees designated by the President of Sage Bionetworks, including any employees serving as an investigator on a federal/Public Health Services award, must review and update the Sage Bionetworks Annual Conflict of Interest Questionnaire. New employees serving as investigators are required to complete a FCOI form within 30 days of their start date. In addition, all investigators must submit an ad hoc disclosure of a Significant Financial Interest they acquire or discover during the course of the year within 30 days of discovering or acquiring the Significant Financial Interest. Forms are reviewed and any potential conflicts are referred to the President and outside counsel.
Form 990, Part VI, Section B, Line 15Executive compensation was set by the Board of Directors Compensation Committee.
Form 990, Part VI, Section C, Line 19The organization's financials are contained within its 990 returns. These returns are available to the public through organizations such as Guidestar, dedicated to publicizing information about nonprofit organizations. The organization's governing documents and conflict of interest policies are available upon request.
Form 990, Part IX, Line 11gScientific Reseach Expenses $1,109,936; Assembly Expenses $179,475; Platform/Scientific Computing Expenses $847,697; Professional Services Expenses $235,191.

Reasonable Cause Explanation ReasonableCauseExplanation

FieldValueIRS element (for citing)
ExplanationCPA Single Audit was not completed until the end of September.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.